Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel
NASDAQ:DOMH

Dominari Q4 2024 Earnings Report

Dominari logo
$2.10 -0.03 (-1.41%)
As of 04:00 PM Eastern
ProfileEarnings HistoryForecast

Dominari EPS Results

Actual EPS
$0.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Dominari Revenue Results

Actual Revenue
$6.56 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dominari Announcement Details

Quarter
Q4 2024
Date
4/15/2025
Time
During Market Hours
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Dominari's next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules.

Conference Call Resources

Dominari Earnings Headlines

Dominari Holdings Stock Price History
August 15, 2026  |  investing.comhttps://www.investing.com/equities/spherix-incorp-historical-data
Dominari Holdings, Inc.: Dominari Year to Date Revenue Increases by 14% Over 2025
August 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69276710-dominari-holdings-inc-dominari-year-to-date-revenue-increases-by-14-over-2025-008.htm
Microscopic footage reveals immune cells destroying cancer cells
Time-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer cells - and early human data revealed up to a 63.7 percent reduction in cancer burden. One NASDAQ-listed biotech's TriKE platform is designed to keep these immune cells locked onto tumors longer. Its next-generation version, showing potential for 10 to 40 times greater potency, has just cleared an important FDA milestone.tc pixel
September 4 at 1:00 AM  |  Market Tactic (Ad)
Dominari Year to Date Revenue Increases by 14% Over 2025
August 11, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/dominari-year-to-date-revenue-increases-by-14-over-2025-302847720.html
New America Acquisition I Corp. Announces Leadership Transition; Kyle Wool Appointed Chief Executive Officer
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339714/0/en/new-america-acquisition-i-corp-announces-leadership-transition-kyle-wool-appointed-chief-executive-officer.html
Dominari Congratulates Powerus on its Multimillion Dollar Contract for Aerial Drone System
August 3, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/dominari-congratulates-powerus-on-its-multimillion-dollar-contract-for-aerial-drone-system-302840995.html
See More Dominari Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dominari? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dominari and other key companies, straight to your email.

About Dominari

Dominari (NASDAQ:DOMH), a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

View Dominari Profile
Earnings Tools